Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2022 17:01 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics宣布ADG20（adintrevimab）是首个在新冠病毒暴露前和暴露后预防和治疗中达到主要终点且具有统计学意义的单克隆抗体，并计划寻求美国紧急使用授权

与安慰剂相比，症状性新冠肺炎风险在暴露前预防中降低了71%，在接触后预防中则降低了75% 在主要疗效分析人群中，与安慰剂相比，轻度至中度新冠肺炎患者的住院或死亡风险降低了66%，在症状出现三天内接受治疗的人群中，住院或死亡风险与安慰剂相比降低了77% 报告了2021年全年和第四季度的财务业绩；预计5.91亿美元的现金和投资将足以为2024年下半年的运营提供资金 ...
March 30, 2022 06:30 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization

Risk of symptomatic COVID-19 was reduced by 71% compared to placebo in pre-exposure prophylaxis and 75% compared to placebo in post-exposure prophylaxis Risk of hospitalization or death in...
March 18, 2022 18:33 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders

WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (NASDAQ: ADGI) today announced that it will hold its 2022 Annual Meeting of Stockholders virtually at 8:30 a.m. Eastern...
February 23, 2022 16:30 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer

WALTHAM, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
February 22, 2022 07:30 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates

Multiple Initiatives Undertaken for ADG20 Assessment, Including Analysis of Clinical Data at 300mg Dose and Exploring Higher Doses of ADG20 in the Clinic Company Pursuing Portfolio of Antibodies in...
February 18, 2022 19:33 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics Announces CEO Succession Plan

WALTHAM, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
January 13, 2022 19:30 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics 總結 ADG20 對 SARS-CoV-2 變種的中和活性，並概述解決 Omicron 的計劃

最近由幾個獨立實驗室發表的刊物顯示 ADG20 具有可與其他抗體相比的效力，具有中和活性，並可保留對 Omicron 的活性目前正在進行對 Omicron 和潛在未來 SARS-CoV-2 變種的多項努力麻省沃爾瑟姆, Jan. 14, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI)...
January 13, 2022 19:30 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics、SARS-CoV-2変異株に対するADG20中和活性の概要とオミクロン株に対処するための取り組みを発表

複数の独立した研究機関による最近の発表によると、ADG20は、オミクロン株に対する活性を保持する他の抗体と同等の効力の中和活性を有するオミクロン株および将来発生する可能性のあるSARS-CoV-2変異株に対応するための複数の取り組みが実施されているマサチューセッツ州ウォルサム発, Jan. 14, 2022 (GLOBE NEWSWIRE) --...
January 13, 2022 19:30 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics, SARS-CoV-2 변이에 대한 ADG20의 중화 활동 종합 보고 및 Omicron 대응 계획 발표

여러 독립 시험기관의 연구 결과, ADG20의 중화 활동 능력치는 Omicron 중화 활동 보유한 기타 항체에 필적할 수준 Omicron 및 기타 SARS-CoV-2 변이 가능성에 대처하기 위해 다각도로 노력 중 미국 매사추세츠주 월섬, Jan. 14, 2022 (GLOBE NEWSWIRE) -- 임상 단계 바이오 제약사로 팬데믹으로 변질 우려가...
January 13, 2022 19:30 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics Divulga Resumo da Atividade Neutralizante do ADG20 Contra Variantes do SARS-CoV-2 e Descreve Iniciativas para Abordar o Omicron

Publicações recentes de vários laboratórios independentes mostram que o ADG20 tem atividade neutralizante com potência comparável a outros anticorpos que retêm atividade contra o Omicron Múltiplos...